INTRODUCTION:Attention deficit hyperactivity disorder (ADHD) is a neuropsychiatric condition subclassified in DSM-IV according to its core symptoms domains as (a) predominantly inattentive (ADHD-IN), (b) predominantly hyperactive/impulsive (ADHD-H), and (c) combined inattentive and hyperactive/impulsive (ADHD-C). Whether these subtypes represent distinct clinical entities or points on a severity continuum is controversial. Divergence in treatment response is a potential indicator of qualitative heterogeneity. This study examined smoking cessation response by ADHD subtype to osmotic-release oral system methylphenidate (OROS-MPH). METHODS:Male and female adult smokers (ADHD-C = 167 and ADHD-IN = 87) were randomized to receive OROS-MPH or placebo as augmentation treatment to nicotine patch and counseling. Logistic regression was conducted to test the effect of OROS-MPH versus placebo on prolonged smoking abstinence by ADHD subtype. RESULTS: The subtypes were similar in baseline demographic, smoking, and psychiatric history but differed in smoking cessation response to OROS-MPH or placebo as a function of nicotine dependence level. The 3-way interaction was significant; χ(2)(1) = 8.22, p < .01. Among highly dependent smokers, the prolonged abstinence rates were greater with OROS-MPH than with placebo in the ADHD-C group (60% vs. 31.3%, respectively, p < .05) but higher with placebo than with OROS-MPH in the ADHD-IN group (60% vs. 11.8%, respectively, p < .01). Abstinence rates did not differ by subtype or treatment among smokers who were less nicotine dependent. CONCLUSION: Contrasting treatment response and divergence in the impact of nicotine dependence level support the hypothesis of ADHD subtypes as distinct clinical entities and may indicate the need and directions for personalized targeted treatments of smokers with ADHD.
RCT Entities:
INTRODUCTION:Attention deficit hyperactivity disorder (ADHD) is a neuropsychiatric condition subclassified in DSM-IV according to its core symptoms domains as (a) predominantly inattentive (ADHD-IN), (b) predominantly hyperactive/impulsive (ADHD-H), and (c) combined inattentive and hyperactive/impulsive (ADHD-C). Whether these subtypes represent distinct clinical entities or points on a severity continuum is controversial. Divergence in treatment response is a potential indicator of qualitative heterogeneity. This study examined smoking cessation response by ADHD subtype to osmotic-release oral system methylphenidate (OROS-MPH). METHODS: Male and female adult smokers (ADHD-C = 167 and ADHD-IN = 87) were randomized to receive OROS-MPH or placebo as augmentation treatment to nicotine patch and counseling. Logistic regression was conducted to test the effect of OROS-MPH versus placebo on prolonged smoking abstinence by ADHD subtype. RESULTS: The subtypes were similar in baseline demographic, smoking, and psychiatric history but differed in smoking cessation response to OROS-MPH or placebo as a function of nicotine dependence level. The 3-way interaction was significant; χ(2)(1) = 8.22, p < .01. Among highly dependent smokers, the prolonged abstinence rates were greater with OROS-MPH than with placebo in the ADHD-C group (60% vs. 31.3%, respectively, p < .05) but higher with placebo than with OROS-MPH in the ADHD-IN group (60% vs. 11.8%, respectively, p < .01). Abstinence rates did not differ by subtype or treatment among smokers who were less nicotine dependent. CONCLUSION: Contrasting treatment response and divergence in the impact of nicotine dependence level support the hypothesis of ADHD subtypes as distinct clinical entities and may indicate the need and directions for personalized targeted treatments of smokers with ADHD.
Authors: Lenard A Adler; Thomas Spencer; Stephen V Faraone; Fred W Reimherr; Douglas Kelsey; David Michelson; Joseph Biederman Journal: J Atten Disord Date: 2005-02 Impact factor: 3.256
Authors: Eric T Moolchan; Aleksandras Radzius; David H Epstein; George Uhl; David A Gorelick; Jean Lud Cadet; Jack E Henningfield Journal: Addict Behav Date: 2002 Jan-Feb Impact factor: 3.913
Authors: William J Barbaresi; Slavica K Katusic; Robert C Colligan; Amy L Weaver; Cynthia L Leibson; Steven J Jacobsen Journal: J Dev Behav Pediatr Date: 2006-02 Impact factor: 2.225
Authors: Heather E Volk; Cynthia Henderson; Rosalind J Neuman; Richard D Todd Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-04-05 Impact factor: 3.568
Authors: Arthur N Westover; T Michael Kashner; Theresa M Winhusen; Richard M Golden; Paul A Nakonezny; Bryon Adinoff; Steven S Henley Journal: Am J Drug Alcohol Abuse Date: 2015-06-11 Impact factor: 3.829
Authors: Sean X Luo; Melanie Wall; Lirio Covey; Mei-Chen Hu; Jennifer M Scodes; Frances R Levin; Edward V Nunes; Theresa Winhusen Journal: Am J Drug Alcohol Abuse Date: 2018-01-25 Impact factor: 3.829
Authors: Andrew W Bergen; Harold S Javitz; Li Su; Yungang He; David V Conti; Neal L Benowitz; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Nicotine Tob Res Date: 2012-12-03 Impact factor: 4.244
Authors: Maggie M Sweitzer; Scott H Kollins; Rachel V Kozink; Matt Hallyburton; Joseph English; Merideth A Addicott; Jason A Oliver; F Joseph McClernon Journal: Neuropsychopharmacology Date: 2017-10-20 Impact factor: 7.853
Authors: Edward V Nunes; Lirio S Covey; Gregory Brigham; Mei-Chen Hu; Frances R Levin; Eugene C Somoza; Theresa M Winhusen Journal: J Clin Psychiatry Date: 2013-10 Impact factor: 4.384